Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 373-380

  Taub, Rebecca ^a   Chiang, Edward ^a   Chabot Blanchet, Malorie ^b   Kelly, Martha J ^a   Reeves, Richard A ^c   Guertin, Marie Claude ^b   Tardif, Jean Claude ^b  

^a Madrigal Pharmaceuticals   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c RAR Consulting LLC   (United States)

Author keywords

Cholesterol; Thyroid hormone receptor agonist; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; HORMONE RECEPTOR STIMULATING AGENT; LIOTHYRONINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MGL 3196; NON HIGH DENSITY LIPOPROTEIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HOLTER MONITORING; HUMAN; LIOTHYRONINE BLOOD LEVEL; LIVER METABOLISM; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN;

CHOLESTEROL; THYROID HORMONE RECEPTOR AGONIST; TRIGLYCERIDES;

ADULT; BODY MASS INDEX; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; MALE; MIDDLE AGED; PATIENT SAFETY; PYRIDAZINES; THYROID GLAND; THYROID HORMONE RECEPTORS BETA; THYROTROPIN; THYROXINE; TIME FACTORS; TRIIODOTHYRONINE; URACIL;

EID: 84884517120     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.056     Document Type: Article

References (30)

1. Waters D.D., Brotons C., Chiang C.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120(1):28-34. Lipid Treatment Assessment Project.
2. Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Ann Intern Med 2009, 150(12):858-868.
3. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14(3):173-194.
4. Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5(3):150-159.
5. Toledo F.G., Sniderman A.D., Kelley D.E. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006, 29(8):1845-1850.
6. Grover G.J., Egan D.M., Sleph P.G., et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology 2004, 145(4):1656-1661.
7. Grover G.J., Mellstrom K., Ye L., et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003, 100(17):10067-10072.
8. Johansson L., Rudling M., Scanlan T.S., et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A 2005, 102(29):10297-10302.
9. Morkin E., Pennock G.D., Spooner P.H., Bahl J.J., Goldman S. Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 2002, 12(6):527-533.
10. Baxter J.D., Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009, 8(4):308-320.
11. Gogakos A.I., Duncan Bassett J.H., Williams G.R. Thyroid and bone. Arch Biochem Biophys 2010, 503(1):129-136.
12. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 116(15):1725-1735.
13. Erion M.D., Cable E.E., Ito B.R., et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A 2007, 104(39):15490-15495.
14. Berkenstam A., Kristensen J., Mellstrom K., et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A 2008, 105(2):663-667.
15. Ladenson P.W., Kristensen J.D., Ridgway E.C., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. NEngl J Med 2010, 362(10):906-916.
16. Bengsston P. "Karo Bio terminates the eprotirome Program" Karo Bio February 14 2012, http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=639535.
17. Kelly M.J., Larigan J.D., Pietranico-Cole S., et al. Discovery and development of MGL-3196, a liver-directed thyroid hormone beta agonist for the treatment of hypercholesterolemia/dyslipidemia and hypertriglyceridemia 2013, Abstracts of Papers, 245th ACS National meeting & Exposition, New Orleans, LA, United States MEDI-280.
18. Taub R., Grimsby J., Larigan J.D., Pietranico S., Dvorozniak M., Conde-Knape K. VIA-3196, a liver-directed thyroid beta agonist for treating cardiometabolic disease. Circulation 2009, 120:S1095.
19. Cazanave S.C., Gores G.J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 2010, 5(1):71-85.
20. Dong B.J. How medications affect thyroid function. West J Med 2000, 172(2):102-106.
21. Kelly G.S. Peripheral metabolism of thyroid hormones: a review. Altern Med Rev 2000, 5(4):306-333.
22. Bianco A.C., Kim B.W. Deiodinases: implications of the local control of thyroid hormone action. JClin Invest 2006, 116(10):2571-2579.
23. Bochukova E., Schoenmakers N., Agostini M., et al. Amutation in the thyroid hormone receptor alpha gene. NEngl J Med 2012, 366(3):243-249.
24. Spencer C.A., LoPresti J.S., Nicoloff J.T., Dlott R., Schwarzbein D. Multiphasic thyrotropin responses to thyroid hormone administration in man. JClin Endocrinol Metab 1995, 80(3):854-859.
25. Goldberg I.J., Huang L.S., Huggins L.A., et al. Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. Endocrinology 2012, 153(11):5143-5149.
26. Semple R., Savage D.B., O'Rahilly S. Sex hormone-binding globulin and risk of type 2 diabetes. NEngl J Med 2009, 361(27):2677. author reply 2677-2678.
27. Mitchell C.S., Savage D.B., Dufour S., et al. Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagia. JClin Invest 2010, 120(4):1345-1354.
28. Cable E.E., Finn P.D., Stebbins J.W., et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009, 49(2):407-417.
29. Islam S., Yesmine S., Khan S.A., Alam N.H., Islam S. Acomparative study of thyroid hormone levels in diabetic and non-diabetic patients. Southeast Asian J Trop Med Public Health 2008, 39(5):913-916.
30. Vatner D.F., Weismann D., Beddow S.A., et al. Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab 2013, 305:89-100.